Prism VC Exec Reflects On Start-Up Opportunities, Pegs $63 Mil. For Devices
This article was originally published in The Gray Sheet
Executive Summary
Prism Venture Partners will tap a $250 mil. cash reserve to fund up to seven emerging device firms
You may also be interested in...
Insulet Will Unveil Its OmniPod Insulin Management System In August
Insulet initially will focus marketing efforts for its OmniPod insulin management system on the approximately one mil. Type 1 diabetics in the U.S. who have resisted insulin pump therapy, the company says
Boston Scientific Retains Right To Absorb Reva Medical Under Equity Deal
Reva Medical's unique slide-and-lock bioabsorbable stent design has attracted equity investment from Boston Scientific, which previously expressed doubts about the viability of the biodegradable stent concept
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”